<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 31 Oct 2024 02:47:47 +0000</lastbuilddate>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this cohort study, the KCCQ had strong psychometric properties in patients with severe TR, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe TR as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as TTVI, in rigorously controlled trials.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4266. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Improving patients' health status is a key goal of treating tricuspid regurgitation (TR). The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a heart failure disease-specific health status measure used to capture the health status impact of TR and the benefit of transcatheter tricuspid valve intervention (TTVI), but its validity in this clinical setting is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the psychometric properties of the KCCQ in patients with TR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from patients with severe TR enrolled in 11 manufacturer-sponsored trials of TTVI. The data were transferred to the US Food and Drug Administration to harmonize and anonymize prior to analysis by an independent center. Data were collected from December 2015 to April 2023, and data analysis was performed from July to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Prespecified analyses included evaluation of internal consistency, reproducibility, responsiveness, construct validity, and predictive validity. Outcomes were determined using Cronbach α, score comparisons, intraclass correlation, Cohen d, Spearman correlations with best available reference measures, and association of scores and changes in scores with risk of subsequent clinical events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study cohort was composed of 2693 patients enrolled in either single-arm (n = 1517) or randomized (n = 1176) investigations of TTVI. Mean (SD) patient age was 78.6 (8.0) years, 1658 of 2693 patients (61.6%) were female, and the mean (SD) baseline KCCQ Overall Summary (KCCQ-OS) score was 50 (23). There was strong internal consistency within individual domains (Cronbach α, .77-.83). Among clinically stable patients between 1 and 6 months, there were small mean changes in KCCQ domain and summary scores (differences of -0.1 to 1.9 points), demonstrating reproducibility. In contrast, domain and summary scores of patients who underwent TTVI showed large improvements at 1 month after treatment (mean changes, 12.1-21.4 points), indicating excellent perceived responsiveness. Construct validity was moderately strong when domains were compared with best available reference measures (Spearman correlations, 0.47-0.69). In both cross-sectional and longitudinal analyses, the KCCQ-OS was associated with clinical events, with lower scores associated with an increased risk of mortality (hazard ratio, 1.34 per 10-point decrement; 95% CI, 1.22-1.47) and heart failure hospitalization (hazard ratio, 1.24 per 10-point decrement; 95% CI, 1.17-1.31).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cohort study, the KCCQ had strong psychometric properties in patients with severe TR, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe TR as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as TTVI, in rigorously controlled trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39476153</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4266>10.1001/jamacardio.2024.4266</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476153</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Kensey Gosch</dc:creator>
<dc:creator>Shannon M Dunlay</dc:creator>
<dc:creator>Danielle M Olds</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>Fraser D Bocell</dc:creator>
<dc:creator>Changfu Wu</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation</dc:title>
<dc:identifier>pmid:39476153</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4266</dc:identifier>
</item>
<item>
<title>Measuring Health Status in Patients With Tricuspid Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476024/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4287. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476024/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39476024</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4287>10.1001/jamacardio.2024.4287</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476024</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Measuring Health Status in Patients With Tricuspid Regurgitation</dc:title>
<dc:identifier>pmid:39476024</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4287</dc:identifier>
</item>
<item>
<title>Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation - a Post-hoc Analysis of the MATTERHORN Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39475706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 30. doi: 10.1161/CIRCULATIONAHA.124.072648. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39475706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39475706</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072648>10.1161/CIRCULATIONAHA.124.072648</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39475706</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Felix Rudolph</dc:creator>
<dc:creator>Martin Geyer</dc:creator>
<dc:creator>Stephan Baldus</dc:creator>
<dc:creator>Valeria Maria De Luca</dc:creator>
<dc:creator>Torsten Doenst</dc:creator>
<dc:creator>Roman Pfister</dc:creator>
<dc:creator>Jan Gummert</dc:creator>
<dc:creator>Mirjam Kessler</dc:creator>
<dc:creator>Peter Boekstegers</dc:creator>
<dc:creator>Edith Lubos</dc:creator>
<dc:creator>Jörg Schröder</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Thomas Walther</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>Ingo Eitel</dc:creator>
<dc:creator>Ulrich Fischer-Rasokat</dc:creator>
<dc:creator>Alexander Bufe</dc:creator>
<dc:creator>Alexander Schmeisser</dc:creator>
<dc:creator>Hüseyin Ince</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Christian Hagl</dc:creator>
<dc:creator>Thilo Noack</dc:creator>
<dc:creator>Sebastian Reith</dc:creator>
<dc:creator>Harald Beucher</dc:creator>
<dc:creator>Hermann Reichenspurner</dc:creator>
<dc:creator>Wolfgang Rottbauer</dc:creator>
<dc:creator>Paul Christian Schulze</dc:creator>
<dc:creator>Wiebke Müller</dc:creator>
<dc:creator>Julia Frank</dc:creator>
<dc:creator>Claudia Michalik</dc:creator>
<dc:creator>Martin Hellmich</dc:creator>
<dc:creator>Thorsten Wahlers</dc:creator>
<dc:creator>Volker Rudolph</dc:creator>
<dc:creator>Christos Iliadis</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation - a Post-hoc Analysis of the MATTERHORN Trial</dc:title>
<dc:identifier>pmid:39475706</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072648</dc:identifier>
</item>
<item>
<title>TAVR in Young Patients With Aortic Stenosis: Appropriate Use or Indication Creep?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39475343/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4300. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39475343/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39475343</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4300>10.1001/jamacardio.2024.4300</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39475343</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert O Bonow</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>TAVR in Young Patients With Aortic Stenosis: Appropriate Use or Indication Creep?</dc:title>
<dc:identifier>pmid:39475343</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4300</dc:identifier>
</item>
<item>
<title>Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39475333/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among US patients receiving BEV TAVR for severe aortic stenosis in the low-surgical risk era, those younger than 65 years represent a small subset. Patients younger than 65 years had a high burden of comorbidities and incurred higher rates of death and readmission at 1 year compared to their older counterparts. These observations suggest that heart team decision-making regarding TAVR for most patients in this age group is clinically valid.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4237. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Guidelines advise heart team assessment for all patients with aortic stenosis, with surgical aortic valve replacement recommended for patients younger than 65 years or with a life expectancy greater than 20 years. If bioprosthetic valves are selected, repeat procedures may be needed given limited durability of tissue valves; however, younger patients with aortic stenosis may have major comorbidities that can limit life expectancy, impacting decision-making.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To characterize patients younger than 65 years who received transcatheter aortic valve replacement (TAVR) and compare their outcomes with patients aged 65 to 80 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This retrospective registry-based analysis used data on 139 695 patients from the Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry, inclusive of patients 80 years and younger undergoing TAVR from August 2019 to September 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Balloon-expandable valve (BEV) TAVR with the SAPIEN family of devices.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Comorbidities (heart failure, coronary artery disease, dialysis, and others) and outcomes (death, stroke, and hospital readmission) of patients younger than 65 years compared to patients aged 65 to 80 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the years surveyed, 13 849 registry patients (5.7%) were younger than 65 years, 125 846 (52.1%) were aged 65 to 80 years, and 101 725 (42.1%) were 80 years and older. Among those younger than 65, the mean (SD) age was 59.7 (4.8) years, and 9068 of 13 849 patients (65.5%) were male. Among those aged 65 to 80 years, the mean (SD) age was 74.1 (4.2) years, and 77 817 of 125 843 patients (61.8%) were male. Those younger than 65 years were more likely to have a bicuspid aortic valve than those aged 65 to 80 years (3472/13 755 [25.2%] vs 9552/125 001 [7.6%], respectively; P &lt; .001). They were more likely to have congestive heart failure, chronic lung disease, diabetes, immunocompromise, and end stage kidney disease receiving dialysis. Patients younger than 65 years had worse baseline quality of life (mean [SD] Kansas City Cardiomyopathy Questionnaire score, 47.7 [26.3] vs 52.9 [25.8], respectively; P &lt; .001) and mean (SD) gait speed (5-meter walk test, 6.6 [5.8] seconds vs 7.0 [4.9] seconds, respectively; P &lt; .001) than those aged 65 to 80 years. At 1 year, patients younger than 65 years had significantly higher readmission rates (2740 [28.2%] vs 23 178 [26.1%]; P &lt; .001) and all-cause mortality (908 [9.9%] vs 6877 [8.2%]; P &lt; .001) than older patients. When propensity matched, younger patients still had higher 1-year readmission rates (2732 [28.2%] vs 2589 [26.8%]; P &lt; .03) with similar mortality to their older counterparts (905 [9.9%] vs 827 [10.1%]; P = .55).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among US patients receiving BEV TAVR for severe aortic stenosis in the low-surgical risk era, those younger than 65 years represent a small subset. Patients younger than 65 years had a high burden of comorbidities and incurred higher rates of death and readmission at 1 year compared to their older counterparts. These observations suggest that heart team decision-making regarding TAVR for most patients in this age group is clinically valid.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39475333/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39475333</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4237>10.1001/jamacardio.2024.4237</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39475333</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Megan Coylewright</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>Abhijeet Dhoble</dc:creator>
<dc:creator>Aaron Horne</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Vinod Thourani</dc:creator>
<dc:creator>Tamim M Nazif</dc:creator>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era</dc:title>
<dc:identifier>pmid:39475333</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4237</dc:identifier>
</item>
<item>
<title>Comparison of strategies for vascular ACCESS closure after transcatheter aortic valve implantation: the ACCESS-TAVI randomized trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39474906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: With regard to the composite of major or minor access-related vascular complications, a combined suture-/plug-based VCD strategy was superior to a suturebased VCD strategy for vascular access closure in patients undergoing TF-TAVI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae784. doi: 10.1093/eurheartj/ehae784. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Data from randomized trials investigating different access closure strategies after transfemoral transcatheter aortic valve implantation (TF-TAVI) remain scarce. In this study, two vascular closure device (VCD) strategies to achieve hemostasis after TF-TAVI were compared.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The ACCESS-TAVI (Comparison of Strategies for Vascular ACCESS Closure after Transcatheter Aortic Valve Implantation) is a prospective, multicenter trial in which patients undergoing TF-TAVI were randomly assigned to a strategy with a combined suture-/plug-based VCD strategy (suture/plug group) using one ProGlideTM/ProStyleTM (Abbott Vascular) and one Angio-Seal® (Terumo) versus a suture-based VCD strategy (suture-only group) using two ProGlidesTM/ProStylesTM. The primary endpoint was a composite of major or minor access site-related vascular complications during index hospitalization according to Valve Academic Research Consortium (VARC)-3 criteria. Key secondary endpoints included time to hemostasis, VARC-3 bleeding type ≥2 and all-cause mortality over 30 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between September 2022 and April 2024, 454 patients were randomized. The primary endpoint occurred in 27% (62/230) in the suture/plug group and 54% (121/224) in the suture-only group (relative risk [RR] 0.55 [95% confidence interval: 0.44;0.68]; p&lt;0.001). Time to hemostasis was significantly shorter in the suture/plug group compared to the suture-only group (108±208 s vs. 206±171 s; p &lt;0.001). At 30 days, bleeding type ≥2 occurred less often in the suture/plug group compared to the sutureonly group (6.2% vs. 12.1%, RR 0.66 [0.43;1.02]; p=0.032), with no significant difference in mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: With regard to the composite of major or minor access-related vascular complications, a combined suture-/plug-based VCD strategy was superior to a suturebased VCD strategy for vascular access closure in patients undergoing TF-TAVI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39474906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39474906</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae784>10.1093/eurheartj/ehae784</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39474906</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Tobias Rheude</dc:creator>
<dc:creator>Hendrik Ruge</dc:creator>
<dc:creator>Niklas Altaner</dc:creator>
<dc:creator>Costanza Pellegrini</dc:creator>
<dc:creator>Hector Alvarez Covarrubias</dc:creator>
<dc:creator>N Patrick Mayr</dc:creator>
<dc:creator>Salvatore Cassese</dc:creator>
<dc:creator>Sebastian Kufner</dc:creator>
<dc:creator>Yousuke Taniguchi</dc:creator>
<dc:creator>Christian Thilo</dc:creator>
<dc:creator>Markus Klos</dc:creator>
<dc:creator>Magdalena Erlebach</dc:creator>
<dc:creator>Simon Schneider</dc:creator>
<dc:creator>Martin Jurisic</dc:creator>
<dc:creator>Karl-Ludwig Laugwitz</dc:creator>
<dc:creator>Rüdiger Lange</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Adnan Kastrati</dc:creator>
<dc:creator>Markus Krane</dc:creator>
<dc:creator>Erion Xhepa</dc:creator>
<dc:creator>Michael Joner</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Comparison of strategies for vascular ACCESS closure after transcatheter aortic valve implantation: the ACCESS-TAVI randomized trial</dc:title>
<dc:identifier>pmid:39474906</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae784</dc:identifier>
</item>
<item>
<title>Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471883/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TriClip was safe and effective in the full randomized cohort of TRILUMINATE Pivotal with significant TR reduction and improvements in six-minute walk distance and health status. Rates of all-cause mortality or TV surgery and HFH through 1 year were not reduced by T-TEER.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 23:S0735-1097(24)10054-X. doi: 10.1016/j.jacc.2024.10.086. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Tricuspid regurgitation (TR) is a right-sided valvular disease independently associated with morbidity and mortality. The TRILUMINATE Pivotal trial is the first randomized, controlled trial assessing the impact of TR reduction with tricuspid transcatheter edge-to-edge repair (T-TEER).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: Outcomes from the full randomized cohort of the TRILUMINATE Pivotal trial have not been previously reported, and the additional enrollment may further support the safety and effectiveness of T-TEER through 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The TRILUMINATE Pivotal trial is an international RCT of T-TEER with the TriClip device in patients with symptomatic, severe TR. Adaptive trial design allowed enrollment past the primary analysis population. The primary outcome was a hierarchical composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalizations (HFH), and quality-of-life improvement measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) at 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between August 21, 2019 and June 29, 2022, 572 subjects were randomized, including the primary cohort (n=350) and subsequent enrollment (n=222). Subjects were elderly (78.1±7.8 years) and predominantly female (58.9%), with atrial fibrillation (87.8%) and prior HFH (23.8%). The primary endpoint was met for the full cohort (win ratio=1.84, p&lt;0.0001). Freedom from all-cause mortality and tricuspid valve surgery through 12 months was 90.6% and 89.9% for the device and control groups, respectively (p=0.82). Annualized HFH rate was comparable between device and control subjects (0.17 vs 0.20 events/patient-year, p=0.40). A significant treatment effect was observed for change in quality of life with 49.5% of device subjects achieving a ≥15-point KCCQ score improvement (compared to 25.6% of control subjects, p&lt;0.0001). All secondary endpoints favored T-TEER: moderate or less TR at 30 days (88.9% vs 5.3%, p&lt;0.0001), KCCQ change at 1 year (13.0±1.4 vs -0.5±1.4 points, p&lt;0.0001), and six-minute walk distance change at 1 year (1.7±7.5 vs -27.4±7.4 meters, p&lt;0.0001). Freedom from major adverse events was 98.9% for T-TEER (vs. performance goal: 90%, p&lt;0.0001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TriClip was safe and effective in the full randomized cohort of TRILUMINATE Pivotal with significant TR reduction and improvements in six-minute walk distance and health status. Rates of all-cause mortality or TV surgery and HFH through 1 year were not reduced by T-TEER.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471883/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471883</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.086>10.1016/j.jacc.2024.10.086</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471883</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Brian K Whisenant</dc:creator>
<dc:creator>Nadira Hamid</dc:creator>
<dc:creator>Hursh Naik</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:creator>Peter Tadros</dc:creator>
<dc:creator>Matthew J Price</dc:creator>
<dc:creator>Gagan D Singh</dc:creator>
<dc:creator>Neil P Fam</dc:creator>
<dc:creator>Saibal Kar</dc:creator>
<dc:creator>Shamir R Mehta</dc:creator>
<dc:creator>Richard Bae</dc:creator>
<dc:creator>Nishant K Sekaran</dc:creator>
<dc:creator>Travis Warner</dc:creator>
<dc:creator>Moody Makar</dc:creator>
<dc:creator>George Zorn</dc:creator>
<dc:creator>Raymond Benza</dc:creator>
<dc:creator>Ulrich P Jorde</dc:creator>
<dc:creator>Patrick M McCarthy</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Qian Ren</dc:creator>
<dc:creator>Phillip M Trusty</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>David H Adams</dc:creator>
<dc:creator>TRILUMINATE Pivotal Investigators</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort</dc:title>
<dc:identifier>pmid:39471883</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.086</dc:identifier>
</item>
<item>
<title>Solidifying our Understanding of T-TEER Outcomes: Insights from the PASTE Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 24:S0735-1097(24)10299-9. doi: 10.1016/j.jacc.2024.10.098. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471882</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.098>10.1016/j.jacc.2024.10.098</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471882</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Solidifying our Understanding of T-TEER Outcomes: Insights from the PASTE Registry</dc:title>
<dc:identifier>pmid:39471882</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.098</dc:identifier>
</item>
<item>
<title>Decreasing Unnecessary Invasive Coronary Angiograms with Photon-Counting Detector Coronary Computed Tomography Angiography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471881/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 18:S0735-1097(24)10052-6. doi: 10.1016/j.jacc.2024.10.084. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471881/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471881</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.084>10.1016/j.jacc.2024.10.084</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471881</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrew J Einstein</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Decreasing Unnecessary Invasive Coronary Angiograms with Photon-Counting Detector Coronary Computed Tomography Angiography</dc:title>
<dc:identifier>pmid:39471881</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.084</dc:identifier>
</item>
<item>
<title>Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471811/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection by simian-human immunodeficiency virus (SHIV). In four macaques with vaccine-induced neutralizing responses, SHIV infection boosted plasma neutralization to 45%-77% breadth (geometric mean 50% inhibitory dilution [ID(50)] ∼100) on a 208-strain panel....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 23:S0092-8674(24)01151-6. doi: 10.1016/j.cell.2024.10.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection by simian-human immunodeficiency virus (SHIV). In four macaques with vaccine-induced neutralizing responses, SHIV infection boosted plasma neutralization to 45%-77% breadth (geometric mean 50% inhibitory dilution [ID<sub>50</sub>] ∼100) on a 208-strain panel. Molecular dissection of these responses by antibody isolation and cryo-electron microscopy (cryo-EM) structure determination revealed 15 of 16 antibody lineages with cross-clade neutralization to be directed toward the fusion-peptide site of vulnerability. In each macaque, isolated antibodies from memory B cells recapitulated the plasma-neutralizing response, with fusion-peptide-binding antibodies reaching breadths of 40%-60% (50% inhibitory concentration [IC<sub>50</sub>] &lt; 50 μg/mL) and total lineage-concentrations estimates of 50-200 μg/mL. Longitudinal mapping indicated that these responses arose prior to SHIV infection. Collectively, these results provide in vivo molecular examples for one to a few B cell lineages affording potent, broadly neutralizing plasma responses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471811/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471811</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.003>10.1016/j.cell.2024.10.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471811</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Hua Wang</dc:creator>
<dc:creator>Cheng Cheng</dc:creator>
<dc:creator>James L Dal Santo</dc:creator>
<dc:creator>Chen-Hsiang Shen</dc:creator>
<dc:creator>Tatsiana Bylund</dc:creator>
<dc:creator>Amy R Henry</dc:creator>
<dc:creator>Colin A Howe</dc:creator>
<dc:creator>Juyun Hwang</dc:creator>
<dc:creator>Nicholas C Morano</dc:creator>
<dc:creator>Daniel J Morris</dc:creator>
<dc:creator>Sergei Pletnev</dc:creator>
<dc:creator>Ryan S Roark</dc:creator>
<dc:creator>Tongqing Zhou</dc:creator>
<dc:creator>Bryan T Hansen</dc:creator>
<dc:creator>Forrest H Hoyt</dc:creator>
<dc:creator>Timothy S Johnston</dc:creator>
<dc:creator>Shuyi Wang</dc:creator>
<dc:creator>Baoshan Zhang</dc:creator>
<dc:creator>David R Ambrozak</dc:creator>
<dc:creator>Jordan E Becker</dc:creator>
<dc:creator>Michael F Bender</dc:creator>
<dc:creator>Anita Changela</dc:creator>
<dc:creator>Ridhi Chaudhary</dc:creator>
<dc:creator>Martin Corcoran</dc:creator>
<dc:creator>Angela R Corrigan</dc:creator>
<dc:creator>Kathryn E Foulds</dc:creator>
<dc:creator>Yicheng Guo</dc:creator>
<dc:creator>Myungjin Lee</dc:creator>
<dc:creator>Yingying Li</dc:creator>
<dc:creator>Bob C Lin</dc:creator>
<dc:creator>Tracy Liu</dc:creator>
<dc:creator>Mark K Louder</dc:creator>
<dc:creator>Marco Mandolesi</dc:creator>
<dc:creator>Rosemarie D Mason</dc:creator>
<dc:creator>Krisha McKee</dc:creator>
<dc:creator>Vinod Nair</dc:creator>
<dc:creator>Sijy O'Dell</dc:creator>
<dc:creator>Adam S Olia</dc:creator>
<dc:creator>Li Ou</dc:creator>
<dc:creator>Amarendra Pegu</dc:creator>
<dc:creator>Nagarajan Raju</dc:creator>
<dc:creator>Reda Rawi</dc:creator>
<dc:creator>Jesmine Roberts-Torres</dc:creator>
<dc:creator>Edward K Sarfo</dc:creator>
<dc:creator>Mallika Sastry</dc:creator>
<dc:creator>Andrew J Schaub</dc:creator>
<dc:creator>Stephen D Schmidt</dc:creator>
<dc:creator>Chaim A Schramm</dc:creator>
<dc:creator>Cindi L Schwartz</dc:creator>
<dc:creator>Sarah C Smith</dc:creator>
<dc:creator>Tyler Stephens</dc:creator>
<dc:creator>Jonathan Stuckey</dc:creator>
<dc:creator>I-Ting Teng</dc:creator>
<dc:creator>John-Paul Todd</dc:creator>
<dc:creator>Yaroslav Tsybovsky</dc:creator>
<dc:creator>David J Van Wazer</dc:creator>
<dc:creator>Shuishu Wang</dc:creator>
<dc:creator>Nicole A Doria-Rose</dc:creator>
<dc:creator>Elizabeth R Fischer</dc:creator>
<dc:creator>Ivelin S Georgiev</dc:creator>
<dc:creator>Gunilla B Karlsson Hedestam</dc:creator>
<dc:creator>Zizhang Sheng</dc:creator>
<dc:creator>Ruth A Woodward</dc:creator>
<dc:creator>Daniel C Douek</dc:creator>
<dc:creator>Richard A Koup</dc:creator>
<dc:creator>Theodore C Pierson</dc:creator>
<dc:creator>Lawrence Shapiro</dc:creator>
<dc:creator>George M Shaw</dc:creator>
<dc:creator>John R Mascola</dc:creator>
<dc:creator>Peter D Kwong</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques</dc:title>
<dc:identifier>pmid:39471811</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.003</dc:identifier>
</item>
<item>
<title>The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471810/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>Type III CRISPR systems provide immunity against genetic invaders through the production of cyclic oligo-adenylate (cA(n)) molecules that activate effector proteins that contain CRISPR-associated Rossman fold (CARF) domains. Here, we characterized the function and structure of an effector in which the CARF domain is fused to an adenosine deaminase domain, CRISPR-associated adenosine deaminase 1 (Cad1). We show that upon binding of cA(4) or cA(6) to its CARF domain, Cad1 converts ATP to ITP, both...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 24:S0092-8674(24)01150-4. doi: 10.1016/j.cell.2024.10.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Type III CRISPR systems provide immunity against genetic invaders through the production of cyclic oligo-adenylate (cA<sub>n</sub>) molecules that activate effector proteins that contain CRISPR-associated Rossman fold (CARF) domains. Here, we characterized the function and structure of an effector in which the CARF domain is fused to an adenosine deaminase domain, CRISPR-associated adenosine deaminase 1 (Cad1). We show that upon binding of cA<sub>4</sub> or cA<sub>6</sub> to its CARF domain, Cad1 converts ATP to ITP, both in vivo and in vitro. Cryoelectron microscopy (cryo-EM) structural studies on full-length Cad1 reveal an hexameric assembly composed of a trimer of dimers, with bound ATP at inter-domain sites required for activity and ATP/ITP within deaminase active sites. Upon synthesis of cA<sub>n</sub> during phage infection, Cad1 activation leads to a growth arrest of the host that prevents viral propagation. Our findings reveal that CRISPR-Cas systems employ a wide range of molecular mechanisms beyond nucleic acid degradation to provide adaptive immunity in prokaryotes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471810/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471810</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.002>10.1016/j.cell.2024.10.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471810</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Christian F Baca</dc:creator>
<dc:creator>Puja Majumder</dc:creator>
<dc:creator>James H Hickling</dc:creator>
<dc:creator>Linzhi Ye</dc:creator>
<dc:creator>Marianna Teplova</dc:creator>
<dc:creator>Sean F Brady</dc:creator>
<dc:creator>Dinshaw J Patel</dc:creator>
<dc:creator>Luciano A Marraffini</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunity</dc:title>
<dc:identifier>pmid:39471810</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.002</dc:identifier>
</item>
<item>
<title>Multiparameter imaging reveals clinically relevant cancer cell-stroma interaction dynamics in head and neck cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471809/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>Epithelial tumors are characterized by abundant inter- and intra-tumor heterogeneity, which complicates diagnostics and treatment. The contribution of cancer-stroma interactions to this heterogeneity is poorly understood. Here, we report a paradigm to quantify phenotypic diversity in head and neck squamous cell carcinoma (HNSCC) with single-cell resolution. By combining cell-state markers with morphological features, we identify phenotypic signatures that correlate with clinical features,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 22:S0092-8674(24)01146-2. doi: 10.1016/j.cell.2024.09.046. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Epithelial tumors are characterized by abundant inter- and intra-tumor heterogeneity, which complicates diagnostics and treatment. The contribution of cancer-stroma interactions to this heterogeneity is poorly understood. Here, we report a paradigm to quantify phenotypic diversity in head and neck squamous cell carcinoma (HNSCC) with single-cell resolution. By combining cell-state markers with morphological features, we identify phenotypic signatures that correlate with clinical features, including metastasis and recurrence. Integration of tumor and stromal signatures reveals that partial epithelial-mesenchymal transition (pEMT) renders disease outcome highly sensitive to stromal composition, generating a strong prognostic and predictive signature. Spatial transcriptomics and subsequent analyses of cancer spheroid dynamics identify the cancer-associated fibroblast-pEMT axis as a nexus for intercompartmental signaling that reprograms pEMT cells into an invasive phenotype. Taken together, we establish a paradigm to identify clinically relevant tumor phenotypes and discover a cell-state-dependent interplay between stromal and epithelial compartments that drives cancer aggression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471809/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471809</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.046>10.1016/j.cell.2024.09.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471809</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Karolina Punovuori</dc:creator>
<dc:creator>Fabien Bertillot</dc:creator>
<dc:creator>Yekaterina A Miroshnikova</dc:creator>
<dc:creator>Mirjam I Binner</dc:creator>
<dc:creator>Satu-Marja Myllymäki</dc:creator>
<dc:creator>Gautier Follain</dc:creator>
<dc:creator>Kai Kruse</dc:creator>
<dc:creator>Johannes Routila</dc:creator>
<dc:creator>Teemu Huusko</dc:creator>
<dc:creator>Teijo Pellinen</dc:creator>
<dc:creator>Jaana Hagström</dc:creator>
<dc:creator>Noemi Kedei</dc:creator>
<dc:creator>Sami Ventelä</dc:creator>
<dc:creator>Antti Mäkitie</dc:creator>
<dc:creator>Johanna Ivaska</dc:creator>
<dc:creator>Sara A Wickström</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multiparameter imaging reveals clinically relevant cancer cell-stroma interaction dynamics in head and neck cancer</dc:title>
<dc:identifier>pmid:39471809</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.046</dc:identifier>
</item>
<item>
<title>The inflammatory and oxidative phenotype of gestational diabetes is epigenetically transmitted to the offspring: role of methyltransferase MLL1-induced H3K4me3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471481/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Such proof-of-concept study shows persistence of MLL1-dependent H3K4me3 in offspring born to GD women, suggesting an epigenetic-driven transmission of maternal phenotype. These findings may pave the way for pharmacological reprogramming of adverse histone modifications to mitigate abnormal phenotypes underlying early ASCVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae688. doi: 10.1093/eurheartj/ehae688. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Hyperglycaemia during gestational diabetes (GD) predisposes women and their offspring to later cardiometabolic disease. The hyperglycaemia-mediated epigenetic changes remain to be elucidated. Methyltransferase MLL1-induced trimethylation of histone 3 at lysine 4 (H3K4me3) activates inflammatory and oxidative phenotype. This epigenetic mark in GD women and its transmission to the offspring were investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Peripheral blood mononuclear cells (PBMC) were collected from GD and control (C) women and also from adolescents born to women of both groups. Endothelial human umbilical vein endothelial cells (HUVEC) and cord blood mononuclear cells (CBMC) were from umbilical cords. The NF-κBp65 and NOX4 expressions were investigated by reverse transcription quantitative polymerase chain reaction and immunofluorescence (IF). MLL1 and H3K4me3 were investigated by immunoblotting and IF. H3K4me3 on NF-κBp65 and NOX4 promoters was studied by chromatin immunoprecipitation. Superoxide anion generation was measured by electron spin resonance spectroscopy. Plasma cytokines were measured by enzyme-linked immunosorbent assay. To investigate the role of MLL1, HUVEC were exposed to inhibitor MM102 or siRNA transfection.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: PBMC, CBMC, and HUVEC showed an increase of NF-κBp65, IL-6, ICAM-1, MCP-1, and VCAM-1 mRNAs. These findings were associated with H3K4me3 enrichment in the promoter of NF-κBp65. Elevated H3K4me3 and cytokine levels were observed in GD adolescents. MLL1 drives H3K4me3 not only on NF-kB p65, but also on NOX4 promoter. Inhibition of MLL1 blunted NF-κBp65 and NOX4 by modulating inflammatory and oxidative phenotype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Such proof-of-concept study shows persistence of MLL1-dependent H3K4me3 in offspring born to GD women, suggesting an epigenetic-driven transmission of maternal phenotype. These findings may pave the way for pharmacological reprogramming of adverse histone modifications to mitigate abnormal phenotypes underlying early ASCVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471481/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471481</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae688>10.1093/eurheartj/ehae688</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471481</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Nadia Di Pietrantonio</dc:creator>
<dc:creator>Julia Sánchez-Ceinos</dc:creator>
<dc:creator>Mariana Shumliakivska</dc:creator>
<dc:creator>Alexander Rakow</dc:creator>
<dc:creator>Domitilla Mandatori</dc:creator>
<dc:creator>Pamela Di Tomo</dc:creator>
<dc:creator>Gloria Formoso</dc:creator>
<dc:creator>Tiziana Bonfini</dc:creator>
<dc:creator>Maria Pompea Antonia Baldassarre</dc:creator>
<dc:creator>Maria Sennström</dc:creator>
<dc:creator>Wael Almahmeed</dc:creator>
<dc:creator>Assunta Pandolfi</dc:creator>
<dc:creator>Francesco Cosentino</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The inflammatory and oxidative phenotype of gestational diabetes is epigenetically transmitted to the offspring: role of methyltransferase MLL1-induced H3K4me3</dc:title>
<dc:identifier>pmid:39471481</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae688</dc:identifier>
</item>
<item>
<title>Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471463/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this multi-centre IPTW analysis, patients with severe ischaemic cardiomyopathy undergoing revascularization by CABG rather than PCI showed improved long-term survival. However, future randomized controlled trials are needed to confirm the effect of any such benefits.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae672. doi: 10.1093/eurheartj/ehae672. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The optimal revascularization strategy in patients with ischaemic cardiomyopathy remains unclear with no contemporary randomized trial data to guide clinical practice. This study aims to assess long-term survival in patients with severe ischaemic cardiomyopathy revascularized by either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Australian and New Zealand Society of Cardiac and Thoracic Surgeons and Melbourne Interventional Group registries (from January 2005 to 2018), patients with severe ischaemic cardiomyopathy [left ventricular ejection fraction (LVEF) &lt;35%] undergoing PCI or isolated CABG were included in the analysis. Those with ST-elevation myocardial infarction and cardiogenic shock were excluded. The primary outcome was long-term National Death Index-linked mortality up to 10 years following revascularization. Risk adjustment was performed to estimate the average treatment effect using propensity score analysis with inverse probability of treatment weighting (IPTW).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 2042 patients were included, of whom 1451 patients were treated by CABG and 591 by PCI. Inverse probability of treatment weighting-adjusted demographics, procedural indication, coronary artery disease extent, and LVEF were well balanced between the two patient groups. After risk adjustment, patients treated by CABG compared with those treated by PCI experienced reduced long-term mortality [adjusted hazard ratio 0.59, 95% confidence interval (CI) 0.45-0.79, P = .001] over a median follow-up period of 4.0 (inter-quartile range 2.2-6.8) years. There was no difference between the groups in terms of in-hospital mortality [adjusted odds ratio (aOR) 1.42, 95% CI 0.41-4.96, P = .58], but there was an increased risk of peri-procedural stroke (aOR 19.6, 95% CI 4.21-91.6, P &lt; .001) and increased length of hospital stay (exponentiated coefficient 3.58, 95% CI 3.00-4.28, P &lt; .001) in patients treated with CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this multi-centre IPTW analysis, patients with severe ischaemic cardiomyopathy undergoing revascularization by CABG rather than PCI showed improved long-term survival. However, future randomized controlled trials are needed to confirm the effect of any such benefits.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471463/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471463</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae672>10.1093/eurheartj/ehae672</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471463</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jason E Bloom</dc:creator>
<dc:creator>Sara Vogrin</dc:creator>
<dc:creator>Christopher M Reid</dc:creator>
<dc:creator>Andrew E Ajani</dc:creator>
<dc:creator>David J Clark</dc:creator>
<dc:creator>Melanie Freeman</dc:creator>
<dc:creator>Chin Hiew</dc:creator>
<dc:creator>Angela Brennan</dc:creator>
<dc:creator>Diem Dinh</dc:creator>
<dc:creator>Jenni Williams-Spence</dc:creator>
<dc:creator>Luke P Dawson</dc:creator>
<dc:creator>Samer Noaman</dc:creator>
<dc:creator>Derek P Chew</dc:creator>
<dc:creator>Ernesto Oqueli</dc:creator>
<dc:creator>Nicholas Cox</dc:creator>
<dc:creator>David McGiffin</dc:creator>
<dc:creator>Silvana Marasco</dc:creator>
<dc:creator>Peter Skillington</dc:creator>
<dc:creator>Alistair Royse</dc:creator>
<dc:creator>Dion Stub</dc:creator>
<dc:creator>David M Kaye</dc:creator>
<dc:creator>William Chan</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival</dc:title>
<dc:identifier>pmid:39471463</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae672</dc:identifier>
</item>
<item>
<title>Transcatheter correction of a rare combined anomalous pulmonary and systemic venous return in an adult</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae732. doi: 10.1093/eurheartj/ehae732. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471415</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae732>10.1093/eurheartj/ehae732</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471415</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Grégoire Albenque</dc:creator>
<dc:creator>Clément Batteux</dc:creator>
<dc:creator>Sébastien Hascoët</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter correction of a rare combined anomalous pulmonary and systemic venous return in an adult</dc:title>
<dc:identifier>pmid:39471415</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae732</dc:identifier>
</item>
<item>
<title>Cardiac manifestation of lysosomal storage disorder</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae743. doi: 10.1093/eurheartj/ehae743. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471408</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae743>10.1093/eurheartj/ehae743</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471408</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Nikhil Singhania</dc:creator>
<dc:creator>A Shaheer Ahmed</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac manifestation of lysosomal storage disorder</dc:title>
<dc:identifier>pmid:39471408</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae743</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: RESHAPing potential treatment indications for functional mitral regurgitation in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471406/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae727. doi: 10.1093/eurheartj/ehae727. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471406/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471406</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae727>10.1093/eurheartj/ehae727</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471406</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: RESHAPing potential treatment indications for functional mitral regurgitation in heart failure</dc:title>
<dc:identifier>pmid:39471406</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae727</dc:identifier>
</item>
<item>
<title>Cerebral Embolic Protection by Geographic Region: A Post Hoc Analysis of the PROTECTED TAVR Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION AND RELEVANCE: The PROTECTED TAVR trial could not show that the use of CEP had a significant effect on the incidence of periprocedural stroke during TAVR. Although there was no significant interaction by geographic region, this exploratory post hoc analysis suggests a trend toward greater stroke reduction in the US cohort but not in the OUS cohort. These findings are hypothesis generating, and further research is needed to determine if regional differences in patient characteristics...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 29. doi: 10.1001/jamacardio.2024.4278. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Transcatheter aortic valve replacement (TAVR) is an established treatment option for many patients with severe symptomatic aortic stenosis; however, debris dislodged during the procedure can cause embolic stroke. The Sentinel cerebral embolic protection (CEP) device is approved for capture and removal of embolic material during TAVR but its efficacy has been debated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To explore regional differences in the association of CEP utilization with stroke outcomes in patients undergoing TAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a prospective, postmarket, randomized clinical trial evaluating TAVR performed with or without the CEP took place at 51 hospitals in the US, Europe, and Australia from February 2020 to January 2022. Patients with symptomatic aortic stenosis treated with transfemoral TAVR were included. Randomization was stratified according to center, operative risk, and intended TAVR valve type. Patients were excluded if the left common carotid or brachiocephalic artery had greater than 70% stenosis or if the anatomy precluded placement of the CEP device. Data for this post hoc study were analyzed from August to October 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: TAVR with or without CEP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was the rate of all stroke events at hospital discharge or 72 hours post-TAVR, whichever came first. Neurological examinations were performed at baseline and postprocedure to identify stroke, disabling stroke, and other neurological outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The Stroke Protection With Sentinel During Transcatheter Aortic Valve Replacement (PROTECTED TAVR) trial enrolled and randomized 3000 patients (1803 [60.1%] male; mean [SD] age, 78.9 [7.8] years): 1833 in the US cohort (TAVR alone: 919, TAVR with CEP: 914) and 1167 patients in the outside the US (OUS) cohort (TAVR alone: 580, TAVR with CEP: 587). Patients in the US cohort were younger, more predominantly male, had a lower prevalence of atrial fibrillation, and had a higher prevalence of bicuspid aortic valve, diabetes, and peripheral vascular disease compared with the OUS cohort. In the main trial, the incidence of stroke within 72 hours after TAVR or before discharge did not differ significantly between the CEP group and the control group, and there was no interaction by geographic region. In this post hoc analysis, patients treated with CEP in the US cohort exhibited a 50% relative risk reduction for overall stroke and a 73% relative risk reduction for disabling stroke compared to TAVR alone; a treatment effect on stroke risk reduction was not observed in the OUS cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: The PROTECTED TAVR trial could not show that the use of CEP had a significant effect on the incidence of periprocedural stroke during TAVR. Although there was no significant interaction by geographic region, this exploratory post hoc analysis suggests a trend toward greater stroke reduction in the US cohort but not in the OUS cohort. These findings are hypothesis generating, and further research is needed to determine if regional differences in patient characteristics or procedural practices affect CEP efficacy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04149535.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39471309</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4278>10.1001/jamacardio.2024.4278</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471309</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Raj R Makkar</dc:creator>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Thomas E Waggoner</dc:creator>
<dc:creator>Samuel Horr</dc:creator>
<dc:creator>Juhana Karha</dc:creator>
<dc:creator>Lowell Satler</dc:creator>
<dc:creator>Robert C Stoler</dc:creator>
<dc:creator>Jorge Alvarez</dc:creator>
<dc:creator>Rahul Sakhuja</dc:creator>
<dc:creator>Lee MacDonald</dc:creator>
<dc:creator>Rodrigo Modolo</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Axel Linke</dc:creator>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cerebral Embolic Protection by Geographic Region: A Post Hoc Analysis of the PROTECTED TAVR Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39471309</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4278</dc:identifier>
</item>
<item>
<title>Large-bore Mechanical Thrombectomy Versus Catheter-directed Thrombolysis in the Management of Intermediate-risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39470698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: PEERLESS met its primary endpoint in favor of LBMT vs CDT in treatment of intermediate-risk PE. LBMT had lower rates of clinical deterioration and/or bailout and postprocedural ICU utilization compared with CDT, with no difference in mortality or bleeding.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29. doi: 10.1161/CIRCULATIONAHA.124.072364. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: There is a lack of randomized controlled trial (RCT) data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism (PE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PEERLESS is a prospective, multicenter, RCT that enrolled 550 intermediate-risk PE patients with right ventricular dilatation and additional clinical risk factors randomized 1:1 to treatment with large-bore mechanical thrombectomy (LBMT) or catheter-directed thrombolysis (CDT). The primary endpoint was a hierarchal win ratio (WR) composite of the following: 1) all-cause mortality, 2) intracranial hemorrhage, 3) major bleeding, 4) clinical deterioration and/or escalation to bailout, and 5) postprocedural intensive care unit (ICU) admission and length of stay, assessed at the sooner of hospital discharge or 7 days post-procedure. Assessments at the 24-hour visit included respiratory rate, mMRC dyspnea score, NYHA classification, right ventricle (RV)/left ventricle (LV) ratio reduction, and RV function. Endpoints through 30 days included total hospital stay, all-cause readmission, and all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The primary endpoint occurred significantly less frequently with LBMT vs CDT (WR 5.01 [95% CI: 3.68-6.97]; <i>P</i>&lt;0.001). There were significantly fewer episodes of clinical deterioration and/or bailout (1.8% vs 5.4%; <i>P</i>=0.04) with LBMT vs CDT and less postprocedural ICU utilization (<i>P</i>&lt;0.001), including admissions (41.6% vs 98.6%) and stays >;24 hours (19.3% vs 64.5%). There was no significant difference in mortality, intracranial hemorrhage, or major bleeding between strategies, nor in a secondary WR endpoint including the first 4 components (WR 1.34 [95% CI: 0.78-2.35]; <i>P</i>=0.30). At the 24-hour visit, respiratory rate was lower for LBMT patients (18.3±3.3 vs 20.1±5.1; <i>P</i>&lt;0.001) and fewer had moderate to severe mMRC dyspnea scores (13.5% vs 26.4%; <i>P</i>&lt;0.001), NYHA classifications (16.3% vs 27.4%; <i>P</i>=0.002), and RV dysfunction (42.1% vs 57.9%; <i>P</i>=0.004). RV/LV ratio reduction was similar (0.32±0.24 vs 0.30±0.26; <i>P</i>=0.55). LBMT patients had shorter total hospital stays (4.5±2.8 vs 5.3±3.9 overnights; <i>P</i>=0.002) and fewer all-cause readmissions (3.2% vs 7.9%; <i>P</i>=0.03), while 30-day mortality was similar (0.4% vs 0.8%; <i>P</i>=0.62).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PEERLESS met its primary endpoint in favor of LBMT vs CDT in treatment of intermediate-risk PE. LBMT had lower rates of clinical deterioration and/or bailout and postprocedural ICU utilization compared with CDT, with no difference in mortality or bleeding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39470698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39470698</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072364>10.1161/CIRCULATIONAHA.124.072364</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39470698</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Wissam A Jaber</dc:creator>
<dc:creator>Carin F Gonsalves</dc:creator>
<dc:creator>Stefan Stortecky</dc:creator>
<dc:creator>Samuel Horr</dc:creator>
<dc:creator>Orestis Pappas</dc:creator>
<dc:creator>Ripal T Gandhi</dc:creator>
<dc:creator>Keith Pereira</dc:creator>
<dc:creator>Jay Giri</dc:creator>
<dc:creator>Sameer J Khandhar</dc:creator>
<dc:creator>Khawaja Afzal Ammar</dc:creator>
<dc:creator>David M Lasorda</dc:creator>
<dc:creator>Brian Stegman</dc:creator>
<dc:creator>Lucas Busch</dc:creator>
<dc:creator>David J Dexter Ii</dc:creator>
<dc:creator>Ezana M Azene</dc:creator>
<dc:creator>Nikhil Daga</dc:creator>
<dc:creator>Fakhir Elmasri</dc:creator>
<dc:creator>Chandra R Kunavarapu</dc:creator>
<dc:creator>Mark E Rea</dc:creator>
<dc:creator>Joseph S Rossi</dc:creator>
<dc:creator>Joseph Campbell</dc:creator>
<dc:creator>Jonathan Lindquist</dc:creator>
<dc:creator>Adam Raskin</dc:creator>
<dc:creator>Jason C Smith</dc:creator>
<dc:creator>Thomas M Tamlyn</dc:creator>
<dc:creator>Gabriel A Hernandez</dc:creator>
<dc:creator>Parth Rali</dc:creator>
<dc:creator>Torrey R Schmidt</dc:creator>
<dc:creator>Jeffrey T Bruckel</dc:creator>
<dc:creator>Juan C Camacho</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Samy Selim</dc:creator>
<dc:creator>Catalin Toma</dc:creator>
<dc:creator>Sukhdeep Singh Basra</dc:creator>
<dc:creator>Brian A Bergmark</dc:creator>
<dc:creator>Bhavraj Khalsa</dc:creator>
<dc:creator>David M Zlotnick</dc:creator>
<dc:creator>Jordan Castle</dc:creator>
<dc:creator>David J O'Connor</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>PEERLESS Committees and Investigators</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Large-bore Mechanical Thrombectomy Versus Catheter-directed Thrombolysis in the Management of Intermediate-risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:39470698</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072364</dc:identifier>
</item>
<item>
<title>Low ambient temperature and incident myocardial infarction with or without obstructive coronary arteries: a Chinese nationwide study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39468415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This nationwide study highlights the particular susceptibility of MINOCA patients to ambient low temperature compared with that of MI-CAD patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 28:ehae711. doi: 10.1093/eurheartj/ehae711. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Although non-optimum ambient temperature is a major non-traditional risk factor for acute myocardial infarction, there is no prior knowledge on whether non-optimum ambient temperature could differentially affect myocardial infarction with obstructive coronary artery disease (MI-CAD) and myocardial infarction with non-obstructive coronary arteries (MINOCA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Chinese Cardiovascular Association database-Chest Pain Center Registry, a nationwide, time-stratified, case-crossover investigation was conducted from 2015 to 2021. Meteorological data were obtained from an established satellite-based model, and daily exposures were assigned according to the onset of myocardial infarction in each patient. A conditional logistic regression model combined with distributed lag non-linear models (10 days) was used to estimate the exposure-response relationships.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 83 784 MINOCA patients and 918 730 MI-CAD patients were included. The risk of MINOCA and MI-CAD associated with low temperature occurred at lag 2 day and lasted to 1 week. Extremely low temperature was associated with a substantially greater odds ratio (OR) of MINOCA [OR 1.58, 95% confidence interval (CI) 1.31-1.90] than MI-CAD (unmatched: OR 1.32, 95% CI 1.23-1.43; equally matched by age and sex: OR 1.25, 95% CI 1.04-1.50), compared with the corresponding reference temperatures (30°C, 35°C, and 30°C). Stronger associations were observed for patients who were aged ≥65 years, female, or resided in the south. There was no significant difference for the impacts of high temperature on MINOCA and MI-CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This nationwide study highlights the particular susceptibility of MINOCA patients to ambient low temperature compared with that of MI-CAD patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39468415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39468415</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae711>10.1093/eurheartj/ehae711</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39468415</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jia Huang</dc:creator>
<dc:creator>Qinglin He</dc:creator>
<dc:creator>Yixuan Jiang</dc:creator>
<dc:creator>Jennifer Ming Jen Wong</dc:creator>
<dc:creator>Jianxuan Li</dc:creator>
<dc:creator>Jiangdong Liu</dc:creator>
<dc:creator>Ruochen Wang</dc:creator>
<dc:creator>Renjie Chen</dc:creator>
<dc:creator>Yuxiang Dai</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Low ambient temperature and incident myocardial infarction with or without obstructive coronary arteries: a Chinese nationwide study</dc:title>
<dc:identifier>pmid:39468415</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae711</dc:identifier>
</item>
<item>
<title>Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030224746&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1412-1415. doi: 10.1161/CIRCULATIONAHA.124.069220. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030224746&v=2.18.0.post9+e462414">39466890</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069220>10.1161/CIRCULATIONAHA.124.069220</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466890</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Elisabetta Patorno</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials</dc:title>
<dc:identifier>pmid:39466890</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069220</dc:identifier>
</item>





























</channel>
</rss>